Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Nanogen Posts Shrunken Q1 Revenue, Sharper Sales, Wider Loss

NEW YORK, April 30 - Nanogen today reported a wider net loss in the first quarter as shrinking revenue outmusceled a surge in product sales.

 

Total revenue for the quarter ended March 31 were $1.5 million compared with $2.9 million in the year-ago period. The decline was the result of an anticipated slowdown in sponsored research programs, Nanogen said.

The company posted $812,000 in product sales, threefold more than the $229,000 it reported one year ago. Helping this increase was the sale seven NanoChip workstations.

 

R&D spending was cut back to $4.3 million in the current first quarter from $4.8 million year over year. Still, Nanogen posted a loss of $7.5 million, or $.35 per share, compared with $6.3 million, or $.30 per share, one year ago.

 

The company said it had $59.5 million in cash, cash equivalents, and short-term investments as of March 31, it said.

 

For more information, may click here.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.